8-KRegulation FDExhibits & Filings

AGILENT TECHNOLOGIES, INC. 8-K Report, Regulation FD Disclosure (Dec 13, 2024)

Filed December 13, 2024For Securities:A

Summary

Agilent Technologies, Inc. has announced a significant reorganization of its operational structure, effective for financial reporting beginning with the quarter ending January 31, 2025. The company is shifting to a market-focused, customer-centric strategy, which will be reflected in three newly defined reportable business segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab. This change aims to better align the company's operations with its strategic goals and provide clearer insights into performance across these key areas. This 8-K filing provides investors with selected unaudited historical financial information recast under these new segments. While this information is being furnished and not formally filed for Section 18 liability, it offers a preview of how Agilent's past performance will be presented moving forward. Investors should note that prior periods will be restated accordingly, enabling a more consistent comparison once the new structure is fully implemented.

Key Highlights

  • 1Agilent Technologies is reorganizing into three new reportable business segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab.
  • 2The new structure is driven by a market-focused and customer-centric strategy.
  • 3Financial reporting will reflect the new segments starting with the fiscal quarter ending January 31, 2025.
  • 4Prior financial periods will be recast to align with the new segment structure for consistent historical comparison.
  • 5The filing includes selected unaudited historical financial information under the new segments for fiscal quarters and years dating back to FY2022.
  • 6This information is furnished under Regulation FD and is not deemed 'filed' for Section 18 purposes.

Frequently Asked Questions

Agilent is reorganizing its operational structure to support a market-focused and customer-centric strategy. This aims to better align the company's business operations with its strategic goals and provide more granular insights into performance across key market areas.

Financial statements will reflect the new reporting structure beginning with the fiscal quarter ending January 31, 2025. Prior periods will also be recast to allow for historical comparability.

The three new reportable segments are: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab.

No, the information contained in this 8-K filing, including the selected financial information, is being furnished under Regulation FD and is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means the company is not subject to the liabilities associated with Section 18 for this disclosed information.